Published in Biomolecules on November 18, 2014
Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases. Semin Immunopathol (2015) 0.84
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc Natl Acad Sci U S A (2017) 0.75
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. Clin Sarcoma Res (2016) 0.75
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS). Sci Rep (2016) 0.75
Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget (2017) 0.75
Mechanisms underlying ubiquitination. Annu Rev Biochem (2001) 18.87
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science (1995) 12.94
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature (1997) 12.73
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The proteasome: paradigm of a self-compartmentalizing protease. Cell (1998) 8.43
Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science (2002) 7.49
A cryptic protease couples deubiquitination and degradation by the proteasome. Nature (2002) 6.21
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell (2010) 4.45
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol (1999) 3.99
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (1993) 3.65
Proteasome from Thermoplasma acidophilum: a threonine protease. Science (1995) 3.62
The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure (2002) 3.44
An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol (2002) 3.22
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
MHC class I expression in mice lacking the proteasome subunit LMP-7. Science (1994) 3.17
Regulation of CD8+ T cell development by thymus-specific proteasomes. Science (2007) 3.11
The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell (2006) 3.09
Structural basis for the activation of 20S proteasomes by 11S regulators. Nature (2000) 3.04
Degradation of oxidized proteins by the 20S proteasome. Biochimie (2001) 2.93
The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell (2001) 2.91
The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem (1997) 2.85
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 2.85
Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature (2004) 2.84
Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol (2009) 2.80
The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem (1999) 2.72
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity (2004) 2.53
Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem (1992) 2.48
Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity (1994) 2.39
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem (1992) 2.35
Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med (1998) 2.32
Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell (2007) 2.31
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem (1999) 2.29
Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med (2001) 2.28
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 2.27
Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med (2004) 2.23
Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem (1994) 2.23
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc Natl Acad Sci U S A (1993) 2.16
PA200, a nuclear proteasome activator involved in DNA repair. EMBO J (2002) 2.15
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (1993) 2.11
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci U S A (1994) 2.08
Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A (1997) 2.08
Molecular architecture and assembly of the eukaryotic proteasome. Annu Rev Biochem (2013) 2.04
Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol (1995) 1.91
Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity (2003) 1.89
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol (1994) 1.83
Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J Biol Chem (2000) 1.83
Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell (2012) 1.83
Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin/ATP-dependent proteases from rabbit reticulocyte lysate. J Biol Chem (1992) 1.81
Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J (2000) 1.80
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell (2013) 1.74
Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci U S A (1998) 1.72
The mouse and human genes encoding the recognition component of the N-end rule pathway. Proc Natl Acad Sci U S A (1998) 1.72
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A (2010) 1.70
Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem (1999) 1.70
A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med (2005) 1.68
Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J (2002) 1.68
Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol (2009) 1.67
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J (2008) 1.65
Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J (2001) 1.65
The immunoproteasome, the 20S proteasome and the PA28αβ proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J (2010) 1.65
The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci U S A (1997) 1.64
Involvement of the nuclear proteasome activator PA28γ in the cellular response to DNA double-strand breaks. Cell Cycle (2011) 1.63
The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci U S A (1999) 1.62
The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J (2000) 1.62
Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity (1995) 1.59
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med (2000) 1.59
The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proc Natl Acad Sci U S A (2011) 1.57
Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J Biol Chem (1998) 1.57
Structure of the proteasome activator REGalpha (PA28alpha). Nature (1997) 1.56
Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol (2000) 1.52
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol (1997) 1.51
Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics (2011) 1.50
Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero-oligomers are heptamers. Biochemistry (1999) 1.49
Regulation of the 26S proteasome complex during oxidative stress. Sci Signal (2010) 1.48
Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J Biol Chem (1997) 1.47
Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol (2004) 1.46
Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol (2011) 1.45
Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol (2000) 1.44
Proteasome disassembly and downregulation is correlated with viability during stationary phase. Curr Biol (2003) 1.44
Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination. J Mol Biol (2009) 1.43
ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity (2006) 1.43